OBJECTIVE: The objective of this study was to evaluate prognostic risk factors for survival in women with low-grade serous epithelial ovarian cancer (LGSC). METHODS: A multicenter retrospective analysis of patients with LGSC was conducted. Potential epidemiologic risk factors evaluated included obesity, age, parity, race, smoking, oral contraceptive pill and/or hormonal replacement therapy use, and previous hysterectomy or surgery on fallopian tubes and/or ovaries. Additional factors included stage, extent of debulking, residual disease, and disease status. RESULTS: Eighty-one patients were identified, and pathologic diagnosis was independently confirmed. Median age at diagnosis was 56 years (range, 21-86 years). Thirty-four percent were obese, and 80% had optimally debulked disease. Forty-six percent were alive, 14% with disease, whereas 25% were dead of disease, 2% died of intercurrent disease, and 27% had an unknown status. In a univariate analysis, optimal surgical debulking was associated with improved progression-free survival (P = 0.01), disease-specific survival (P = 0.03), and overall survival (OS) (P < 0.001) and body mass index with worse OS (P = 0.05). On multivariate analysis, obesity (hazard ratio, 2.8; 95% confidence interval, 1.05-7.3; P = 0.04) and optimal tumor debulking (hazard ratio, 0.05; 95% confidence interval, 0.008-0.29; P = 0.001) were a significant predictor of OS. CONCLUSIONS: In a multivariate analysis, obesity and optimal tumor cytoreduction were significant predictors of OS. However, obesity was not associated with worse disease-specific survival, suggesting that mortality of obese patients with LGSC may result from other comorbidities. Interventions addressing obesity may improve survival for women diagnosed with LGSC, and further study is warranted to address the role of obesity in LGSC.
OBJECTIVE: The objective of this study was to evaluate prognostic risk factors for survival in women with low-grade serous epithelial ovarian cancer (LGSC). METHODS: A multicenter retrospective analysis of patients with LGSC was conducted. Potential epidemiologic risk factors evaluated included obesity, age, parity, race, smoking, oral contraceptive pill and/or hormonal replacement therapy use, and previous hysterectomy or surgery on fallopian tubes and/or ovaries. Additional factors included stage, extent of debulking, residual disease, and disease status. RESULTS: Eighty-one patients were identified, and pathologic diagnosis was independently confirmed. Median age at diagnosis was 56 years (range, 21-86 years). Thirty-four percent were obese, and 80% had optimally debulked disease. Forty-six percent were alive, 14% with disease, whereas 25% were dead of disease, 2% died of intercurrent disease, and 27% had an unknown status. In a univariate analysis, optimal surgical debulking was associated with improved progression-free survival (P = 0.01), disease-specific survival (P = 0.03), and overall survival (OS) (P < 0.001) and body mass index with worse OS (P = 0.05). On multivariate analysis, obesity (hazard ratio, 2.8; 95% confidence interval, 1.05-7.3; P = 0.04) and optimal tumor debulking (hazard ratio, 0.05; 95% confidence interval, 0.008-0.29; P = 0.001) were a significant predictor of OS. CONCLUSIONS: In a multivariate analysis, obesity and optimal tumor cytoreduction were significant predictors of OS. However, obesity was not associated with worse disease-specific survival, suggesting that mortality of obesepatients with LGSC may result from other comorbidities. Interventions addressing obesity may improve survival for women diagnosed with LGSC, and further study is warranted to address the role of obesity in LGSC.
Authors: James C Pavelka; Rebecca S Brown; Beth Y Karlan; Ilana Cass; Ronald S Leuchter; Leo D Lagasse; Andrew J Li Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: David M Gershenson; Charlotte C Sun; Karen H Lu; Robert L Coleman; Anil K Sood; Anais Malpica; Michael T Deavers; Elvio G Silva; Diane C Bodurka Journal: Obstet Gynecol Date: 2006-08 Impact factor: 7.661
Authors: Marta A Crispens; Diane Bodurka; Michael Deavers; Karen Lu; Elvio G Silva; David M Gershenson Journal: Obstet Gynecol Date: 2002-01 Impact factor: 7.661
Authors: Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva Journal: Am J Surg Pathol Date: 2004-04 Impact factor: 6.394
Authors: Lucía Robado de Lope; Olwen Leaman Alcíbar; Ana Amor López; Marta Hergueta-Redondo; Héctor Peinado Journal: Philos Trans R Soc Lond B Biol Sci Date: 2018-01-05 Impact factor: 6.237
Authors: Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado Journal: Curr Oncol Rep Date: 2016-02 Impact factor: 5.075
Authors: Fausto Petrelli; Alessio Cortellini; Alice Indini; Gianluca Tomasello; Michele Ghidini; Olga Nigro; Massimiliano Salati; Lorenzo Dottorini; Alessandro Iaculli; Antonio Varricchio; Valentina Rampulla; Sandro Barni; Mary Cabiddu; Antonio Bossi; Antonio Ghidini; Alberto Zaniboni Journal: JAMA Netw Open Date: 2021-03-01
Authors: Stephanie Stelten; Christelle Schofield; Yvonne A W Hartman; Pedro Lopez; Gemma G Kenter; Robert U Newton; Daniel A Galvão; Meeke Hoedjes; Dennis R Taaffe; Luc R C W van Lonkhuijzen; Carolyn McIntyre; Laurien M Buffart Journal: Cancers (Basel) Date: 2022-09-20 Impact factor: 6.575